Involving General Or Homologous Recombination (e.g., Gene Targeting, Etc.) Patents (Class 435/463)
  • Publication number: 20140193913
    Abstract: The methods and compositions described herein are based, in part, on the discovery of a stem cell state in human cells that resembles the morphology observed in murine-derived stem cells. Induction of such a state in human stem cells permits an increase in the efficiency of homologous recombination. Thus, the methods and compositions described herein relate to cells and methods for increasing the efficiency of homologous recombination in human stem cells.
    Type: Application
    Filed: August 16, 2013
    Publication date: July 10, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Niels Geijsen, Christa Buecker
  • Patent number: 8765448
    Abstract: Methods and means are provided for the exact exchange in eukaryotic cells, such as plant cells, of a target DNA sequence for a DNA sequence of interest through homologous recombination, whereby the selectable or screenable marker used during the homologous recombination phase for temporal selection of the gene replacement events can subsequently be removed without leaving a foot-print employing a method for the removal of a selected DNA flanked by two nucleotide sequences in direct repeats.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: July 1, 2014
    Assignee: Bayer Cropscience, N.V.
    Inventors: Anne Rolland, Manuel Dubald, Michiel Van Lookeren Campagne, Rene Ruiter
  • Patent number: 8759105
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: June 24, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, David Frendewey, George D. Yancopoulos
  • Patent number: 8728820
    Abstract: The invention provides a method for inserting a single stranded replacement nucleic acid into a target nucleic acid, the method comprising the steps of: a) generating a single stranded replacement nucleic acid from a double stranded nucleic acid, wherein the double stranded nucleic acid is adapted at one or both of its 5? ends such that preferential degradation of one strand and/or strand separation generates the single stranded replacement nucleic acid, wherein the single stranded replacement nucleic acid comprises a 5? region that is identical to sequence on the target nucleic acid, a 3? region that is identical to sequence on the target nucleic acid and optionally a replacement region between the 5? and 3? regions that is not identical to sequence on the target nucleic acid, b) exposing the target nucleic acid to the single stranded replacement nucleic acid under conditions suitable for recombination to occur between the single stranded replacement nucleic acid and the target nucleic acid, and c) selecting
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: May 20, 2014
    Assignee: Gene Bridges GmbH
    Inventors: Marcello Maresca, Axel Steffen Erler, Jun Fu, Philipp Martin Seibert, Adrian Francis Stewart, Youming Zhang
  • Patent number: 8722964
    Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: May 13, 2014
    Assignee: Transposagen Biopharmaceuticals, Inc.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Patent number: 8715972
    Abstract: Provided is a lactic acid bacterium capable of homolactic fermentation using a pentose as a substrate, the lactic acid bacterium utilizing a pentose, and in which a phosphoketolase pathway is blocked and a pentose phosphate pathway is activated. Also provided is a method for producing lactic acid from a pentose using the lactic acid bacterium and a method for preparing the lactic acid bacterium.
    Type: Grant
    Filed: February 15, 2010
    Date of Patent: May 6, 2014
    Assignees: Bio-energy Corporation, Kansai Chemical Engineering Co., Ltd.
    Inventors: Akihiko Kondo, Kenji Okano, Hideo Noda
  • Patent number: 8703489
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: April 22, 2014
    Assignee: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Patent number: 8697851
    Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 15, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, David Jonathan Heslin, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 8669418
    Abstract: The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: March 11, 2014
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Patent number: 8658155
    Abstract: Methods and compositions for producing selected non-human mammalian germ cells and gametes and for making non-human animals using the produced germ cells and gametes are provided by the present invention. Methods of generating a non-human embryo and/or animal derived from donor stem cells, methods of generating chimeric non-human animals having substantially all gametes and/or germ cells derived from the donor stem cells, methods of producing a non-human host embryo lacking functional endogenous germ cells and non-human host embryos incapable of developing endogenous gametes of the present invention are described herein.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: February 25, 2014
    Assignee: The Jackson Laboratory
    Inventors: Michael V. Wiles, Robert Taft
  • Patent number: 8604281
    Abstract: A process of producing transgenic multi-cellular plants or parts thereof expressing a trait of interest that has a controlled distribution of said trait to progeny, comprising (i) producing a first plant or a cell thereof having in a first locus of a nuclear chromosome a first heterologous nucleotide sequence comprising a first fragment of a nucleotide sequence encoding said trait of interest, (ii) producing a second plant or a cell thereof having in a second locus of a nuclear chromosome homologous to said nuclear chromosome of step (i), a second heterologous nucleotide sequence comprising a second fragment of the nucleotide sequence encoding said trait of interest, and (iii) hybridising said first and said second plants or cells thereof to generate progeny exhibiting said functional trait of interest. Also disclosed is a process of producing hybrid seeds for agriculture.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: December 10, 2013
    Assignee: Bayer CropScience NV
    Inventors: Stefan Werner, Anatoly Giritch, Serik Eliby, Sylvestre Marillonnet, Victor Klimyuk, Yuri Gleba
  • Publication number: 20130316366
    Abstract: Some embodiments herein provide compositions and methods for expressing secreted and cell-surface-bound polypeptides in a single cell. In some embodiments, secreted and cell-surface polypeptide are produced from a single polynucleotide. The polynucleotide can comprise a sequence (or sequence encoding a polypeptide) that mediates separation of a membrane anchor from the polypeptide. In some embodiments, a desired ratio of secreted to surface-bound polypeptide is obtained by selecting a sequence that mediates a desired level of separation of the membrane anchor from the polypeptide.
    Type: Application
    Filed: May 24, 2013
    Publication date: November 28, 2013
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Kenneth Yu, David Baltimore, Lili Yang
  • Publication number: 20130309670
    Abstract: Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an LTVEC and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.
    Type: Application
    Filed: April 25, 2013
    Publication date: November 21, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, David M. Valenzuela, George D. Yancopoulos
  • Publication number: 20130295675
    Abstract: The present invention provides reagents and methods for improved homologous recombination.
    Type: Application
    Filed: June 26, 2013
    Publication date: November 7, 2013
    Applicants: Arizona State
    Inventors: Bertram JACOBS, Stacy WHITE, Kip CONWELL, Jeffrey LANGLAND, James JANCOVICH
  • Patent number: 8557512
    Abstract: This invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating IRS2 activity in cells and tissues in the body. IRS1 and IRS2 are part of the insulin or insulin-like growth factor signaling pathway. By upregulating the levels or functional activity of IRS2, insulin is used more efficiently by the body to control nutrient levels. By upregulating IRS2 levels or functional activity in pancreatic ?-cells, glucose sensing and insulin secretion are enhanced.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: October 15, 2013
    Assignee: HMI Medical Innovations, LLC
    Inventors: Gerard M. Housey, Morris F. White
  • Patent number: 8546645
    Abstract: The present invention relates to transgenic plants comprising a plurality of nucleic acids heterologous to said plant, each of said nucleic acid comprising a coding sequence operably linked to one or more regulatory elements for directing expression of said coding sequence in said plant, said nucleic acid being stably integrated at or adjacent to rDNA sequences, or a seed, organ, tissue, part or cell thereof, or a descendant of said plant, seed, organ, tissue, part or cell; methods of producing the transgenic plants; and methods of producing oil using the transgenic plants.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: October 1, 2013
    Assignee: Agrisoma Biosciences Inc.
    Inventors: Steven Fabijanski, Michael Lindenbaum, Ping Fu, Elizabeth-France Marillia
  • Patent number: 8541237
    Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 24, 2013
    Assignee: National Cancer Center
    Inventors: In-Hoo Kim, Seong-Wook Lee, Seung-Hee Hong, Jin-Sook Jeong, Yoon-Jong Lee, Yeon-Su Lee, Haeng-Im Jung
  • Publication number: 20130244246
    Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.
    Type: Application
    Filed: December 21, 2012
    Publication date: September 19, 2013
    Applicant: TRANSGENE S.A.`
    Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
  • Patent number: 8524500
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: September 3, 2013
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Fyodor Urnov, Michael C. Holmes, Jeffrey C. Miller, Carl O. Pabo
  • Patent number: 8524368
    Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: September 3, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David M. Lynn, Adam D. Miller
  • Publication number: 20130209437
    Abstract: A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ±8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy.
    Type: Application
    Filed: January 17, 2013
    Publication date: August 15, 2013
    Applicant: CELLECTIS
    Inventor: Cellectis
  • Publication number: 20130212725
    Abstract: The present invention relates to a method of modifying a target sequence in the genome of a eukaryotic cell, the method comprising the step: (a) introducing into the cell a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease or a nucleic acid molecule encoding the fusion protein in expressible form, wherein the fusion protein specifically binds within the target sequence and introduces a double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the modification of the target sequence is by homologous recombination with a donor nucleic acid sequence further comprising the step: (b) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence.
    Type: Application
    Filed: June 7, 2011
    Publication date: August 15, 2013
    Applicant: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND
    Inventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
  • Patent number: 8476072
    Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: July 2, 2013
    Assignee: Cellectis
    Inventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
  • Publication number: 20130130388
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 23, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Regeneron Pharmaceuticals, Inc.
  • Patent number: 8420884
    Abstract: Methods for screening compounds to treat an oncological disorder regulated through a tumor-inducing pathway are provided. The compounds are administered to non-human animal subjects having a disease model, so that the subjects display pathology symptoms that correspond to the oncological disorder in humans. The subjects carry a regulatable transgene expression, of which is associated with tumor formation, and further carry regulatable genes for suppression of tumor formation. The disease-pathology symptoms are induced using a site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the genes for suppression of the tumor formation. The methods further involve analyzing tumor formation in subjects administered the compound and comparing appearance and amount of tumors in the subjects administered the compound with control subjects not administered the compound.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 16, 2013
    Assignee: Tufts Medical Center Inc.
    Inventor: Alain Charest
  • Patent number: 8420782
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 16, 2013
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Patent number: 8409861
    Abstract: Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: April 2, 2013
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Dmitry Guschin, Michael C. Holmes
  • Patent number: 8377674
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: February 19, 2013
    Assignee: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga
  • Publication number: 20130040302
    Abstract: Methods for producing engineered induced pluripotent stem (iPS) cells are provided comprising introducing a first nucleic acid into somatic cells for integration into their genome and reprogramming the cells to produce engineered iPS cells having the nucleic acid integrated into their genome. For example, in certain aspects the cells are reprogrammed by introduction of a genetic element that expresses one or more reprogramming factor and culturing of the cells under conditions sufficient to produce reprogrammed cells.
    Type: Application
    Filed: July 11, 2012
    Publication date: February 14, 2013
    Inventors: Thomas J. Burke, Michael Miller, Michael McLachlan, Sarah Jane Dickerson, Anne Strouse
  • Patent number: 8361751
    Abstract: A cell in which the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is more decreased or deleted than its parent cell; a process for producing an antibody composition using the cell; a transgenic non-human animal or plant or the progenies thereof, in which genome is modified so as to have a decreased or deleted activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body; a process for producing an antibody composition from the animal or plant; and a medicament comprising the antibody composition.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: January 29, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Katsuhiro Mori
  • Patent number: 8338138
    Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: December 25, 2012
    Assignee: The John Hopkins University
    Inventors: Marc A. Ostermeier, Gurkan Guntas
  • Patent number: 8334428
    Abstract: Methods and compositions reduce copy number of transgenes and minimizing vector backbone sequences in plant transformation. Agrobacterium strains with T-DNA integrated into the chromosomal DNA of the Agrobacterium reduce the copy number and vector backbone sequences. Chromosomal integration vectors to integrate T-DNA into a specific locus of Agrobacterium chromosome are disclosed.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: December 18, 2012
    Assignees: Purdue Research Foundation, Iowa State University Research Foundation, Inc.
    Inventors: Stanton B. Gelvin, Heiko Oltmanns, Lan Ying Lee, Bronwyn Frame, Kan Wang
  • Patent number: 8329986
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into a plant Zp15 locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: December 11, 2012
    Assignees: Dow AgroSciences, LLC, Sangamo BioSciences, Inc.
    Inventors: Holly J. Butler, David R. Corbin, Yannick Doyon, Zhifang Gao, Vipula K. Shukla, Fyodor Urnov, Sarah E. Worden
  • Patent number: 8309356
    Abstract: Compositions and methods for targeted gene therapy are disclosed. Compositions containing double duplex-forming pseudocomplementary oligonucleotides are administered in combination with a donor oligonucleotide that is homologous to a target sequence on a double-stranded DNA molecule in need of repair or replacement. By activating cellular mechanisms involved in DNA synthesis, repair and recombination, the double duplex-forming pseudocomplementary oligonucleotides can introduce one or more mutations at a site of interest by increasing the efficiency of targeted recombination of the donor oligonucleotide. The pseudocomplementary oligonucleotides/donor oligonucleotide compositions may be administered in combination with a second therapeutic agent that enhances access of the pseudocomplementary oligonucleotides and/or the donor oligonucleotide to the target site, an agent that enhances or increases DNA repair or recombination, or an agent that enhances uptake or delivery of the oligonucleotides.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: November 13, 2012
    Assignee: Yale University
    Inventor: Peter M. Glazer
  • Publication number: 20120282698
    Abstract: A method to construct eukaryotic cells having a target sequence in a chromosomal DNA sequence replaced by a desired replacement sequence is disclosed.
    Type: Application
    Filed: May 11, 2012
    Publication date: November 8, 2012
    Applicant: DSM IP ASSETS B.V.
    Inventors: Marco Alexander van den BERG, Richard KERKMAN, Hesselien TOUW-RIEL
  • Publication number: 20120270264
    Abstract: Disclosed is a DNA construct that is useful for efficient production of recombinant CHO cells useful for the production of target proteins. The DNA construct is a construct comprising, from a 5? end toward a 3? end, a first homologous DNA fragment, a target protein gene, and a second homologous DNA fragment. The first and second homologous DNA fragments have homology allowing for homologous recombination with a part of a hypoxanthine-phosphoribosyltransferase enzyme (hprt) locus in a CHO cell genome and have a chain length of not less than 1 kbp.
    Type: Application
    Filed: September 21, 2010
    Publication date: October 25, 2012
    Applicant: TOTO LTD.
    Inventors: Shuji Sonezaki, Yumi Ogami, Yoshimasa Yamana, Junya Narita
  • Patent number: 8288160
    Abstract: The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: October 16, 2012
    Assignee: Medical Research Council
    Inventors: Svend K. Petersen-Mahrt, Reuben Harris, Michael Samuel Neuberger, Rupert Christopher Landsdowne Beale
  • Publication number: 20120252123
    Abstract: The present invention features compositions and methods for introducing, into cells, nucleic acids whose expression results in chromosomal silencing. The nucleic acids are targeted to specific chromosomal regions where they subsequently reduce the expression of deleterious genes, or cause the death of deleterious cells. Where the nucleic acid sequence is a silencing sequence, it may encode an Xist RNA or other non-coding, silencing RNA. Accordingly, the present invention features, inter alia, nucleic acid constructs that include a transgene (e.g., a silencing sequence encoding an Xist RNA or other non-coding RNA that silences a segment of a chromosome); first and second sequences that direct insertion of the silencing sequence into a targeted chromosome; and, optionally, a selectable marker.
    Type: Application
    Filed: May 30, 2012
    Publication date: October 4, 2012
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Jeanne B. Lawrence, Lisa L. Hall
  • Patent number: 8247232
    Abstract: A process to prepare a recombined transgenic Zea mays plant or plant cell from a first transgenic Zea mays plant cell, wherein the transgene in the recombinant plant or plant cell has an altered genetic structure relative to the genetic structure of the transgene in the first transgenic plant cell, due to homologous recombination-mediated transgene deletion.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: August 21, 2012
    Assignee: Monsanto Technology LLC
    Inventor: Larry A. Gilbertson
  • Patent number: 8232448
    Abstract: This application is in the field of sialic acid chemistry, metabolism, antigenicity, and the production of transgenic non-human mammals with altered sialic acid production. More particularly, this application relates to N-glycolylneuraminic acid (Neu5Gc) being an immunogen in humans, and the production of Neu5Gc-free mammalian products for laboratory and human use.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: July 31, 2012
    Assignee: The Regents of the University of California
    Inventors: Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
  • Publication number: 20120178169
    Abstract: Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Inventors: Daniel F. Voytas, Adam J. Bogdanove, Feng Zhang
  • Publication number: 20120142110
    Abstract: A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 7, 2012
    Inventors: David B. Avner, Sven Bocklandt, James Kehler
  • Patent number: 8193410
    Abstract: A process of producing a transgenic multi-cellular plants or parts thereof expressing a trait of interest, said trait having a controlled distribution of said trait to progeny, wherein said process comprises (i) producing a first plant or a cell thereof having in a first locus of a nuclear chromosome a first heterologous nucleotide sequence comprising a first fragment of a nucleotide sequence encoding said trait of interest, (ii) producing a second plant or a cell thereof having in a second locus of a nuclear chromosome homologous to said nuclear chromosome of step (i), a second heterologous nucleotide sequence comprising a second fragment of the nucleotide sequence encoding said trait of interest, and (iii) hybridising said first and said second plant or cells thereof to generate progeny exhibiting said functional trait of interest due to binding between a protein or polypeptide encoded by said first heterologous nucleotide sequence and a protein or polypeptide encoded by said second heterologous nucleotide
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: June 5, 2012
    Assignee: Icon Genetics GmbH
    Inventors: Stefan Werner, Anatoly Giritch, Serik Eliby, Sylvestre Marillonnet, Victor Klimyuk, Yuri Gleba
  • Patent number: 8158404
    Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: April 17, 2012
    Assignee: Gevo, Inc.
    Inventors: Doug Lies, Stephanie Porter-Scheinman, Julie Kelly, Catherine Asleson Dundon, Aristos Aristidou, Andrew Hawkins
  • Patent number: 8153415
    Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: April 10, 2012
    Assignee: Gevo, Inc.
    Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
  • Patent number: 8143480
    Abstract: This invention relates to methods for knock-down of a target gene in plants, particularly efficient and specific methods for knock-down of a target gene in plants. This invention also relates to methods for silencing endogenous plant genes or plant pathogen genes. It further relates to nucleic acid constructs (DNA, RNA) which comprise a nucleic acid sequence that corresponds to a target gene or fragment thereof flanked by two complementary sites to an smRNA, e.g., a miRNA (one complementary site is on either side of the nucleic acid sequence), resulting in, for example the configuration: complementary site—nucleic acid sequence that corresponds to a target gene—complementary site.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: March 27, 2012
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Michael Axtell, David P. Bartel
  • Patent number: 8133715
    Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: March 13, 2012
    Assignee: Gevo, Inc.
    Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
  • Patent number: 8105831
    Abstract: The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: January 31, 2012
    Assignee: University of Washington
    Inventors: David W. Russell, Roli K. Hirata
  • Patent number: 8097277
    Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: January 17, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David M. Lynn, Adam D. Miller
  • Patent number: 8097460
    Abstract: The present invention relates to the production of ethanol as a product of bacterial fermentation. In particular this invention relates to a novel method of gene inactivation and gene expression based upon homologous recombination. The method is particularly useful in connection with species of Bacillus such as B. stereothermophilus, B. calvodelox, B. caldotenax, B. thermoglucosidasius, B. coagulans, B. licheniformis, B. thermodenitrificans, and B. caldolyticus.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: January 17, 2012
    Assignee: Elsworth Biotechnology Limited
    Inventors: Muhammed Javed, Fiona Cusdin, Paul Milner, Edward Green